Celularity (NASDAQ:CELU) (NASDAQ: CELU) is a clinical-stage biotechnology company focused on developing allogeneic, off-the-shelf cell therapies leveraging placental-derived cells and proprietary technology platforms. The company’s lead programs address oncology, infectious disease and regenerative medicine, with a particular emphasis on natural killer (NK) cell therapies designed to target hematologic malignancies and solid tumors. Celularity’s approach aims to deliver potent immunotherapeutic and regenerative solutions through scalable cell banks rather than patient-specific products.
Among its pipeline candidates is CYNK-001, an off-the-shelf NK cell therapy in development for a range of blood cancers and solid tumors, and the CELL-001 platform, featuring mesenchymal-like cells intended to support tissue repair and immune modulation. In parallel, Celularity is advancing red blood cell therapies derived from placental stem cells, with the goal of addressing shortages in transfusion medicine. These investigational products leverage the inherent regenerative and immunomodulatory properties of placental cells to offer potential advantages in consistency, availability and cost over autologous approaches.
Founded in 2018 as a spin-out from Celgene’s cell therapy operations, Celularity was co-founded by Dr. Robert Hariri, a physician-scientist with extensive experience in immunology and regenerative medicine, and investor Kevin Kimberlin. The company’s leadership team combines deep expertise in cell biology, clinical development, regulatory affairs and manufacturing. Under the guidance of its board and executive officers, Celularity completed a public listing through a SPAC merger in 2020 and has since established strategic partnerships to advance its clinical programs.
Headquartered in Florham Park, New Jersey, with additional research, development and manufacturing facilities in Warren, New Jersey, Celularity also collaborates with clinical and commercial partners in Asia and Europe. The company places strong emphasis on compliant, scalable GMP manufacturing and robust quality systems to support ongoing global clinical trials and anticipated product approvals, positioning itself to bring innovative cell therapies to patients worldwide.
